Association Between Uric Acid to HDL-C Ratio and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Cross-Sectional Study.

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-05-07 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S520688

Xiangyun Zhu, Han Yin, Jing Han, Xiaoyan Zhang, Qing Han, Weixia Sun, Yijun Liu, Wenxuan Tao, Xinliang Liu, Guofeng Wang, Ling Li

{"title":"Association Between Uric Acid to HDL-C Ratio and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Cross-Sectional Study.","authors":"Xiangyun Zhu, Han Yin, Jing Han, Xiaoyan Zhang, Qing Han, Weixia Sun, Yijun Liu, Wenxuan Tao, Xinliang Liu, Guofeng Wang, Ling Li","doi":"10.2147/DMSO.S520688","DOIUrl":null,"url":null,"abstract":"Background: Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). The uric acid to high-density lipoprotein cholesterol ratio (UHR) has emerged as a novel metabolic biomarker implicated in MASLD pathogenesis. This study aimed to evaluate the association between UHR and MASLD in a T2DM population.Methods: In this cross-sectional study, we analyzed clinical data from 1081 T2DM patients (464 without MASLD, 617 with MASLD). Physiological and biochemical parameters were collected and analyzed. UHR was calculated as [uric acid (mg/dL)/HDL-C (mg/dL)] × 100%. Univariate and multivariate logistic regression analyses were performed to examine the association between UHR and MASLD.Results: T2DM patients with MASLD had significantly higher UHR levels than those without MASLD (12.12[9.06-16.83] vs 10.36[7.65-14.08], p<0.001). UHR showed a strong positive correlation with TG/HDL (r =0.673, p < 0.001), moderate correlations with TG (r = 0.516, p < 0.001) and TC/HDL (r =0.548, p < 0.001), weak but significant associations with BMI (r = 0.330), WHR (r = 0.289), HOMA-IR (r = 0.121), ALT (r = 0.123), and GGT (r = 0.267) (all p < 0.05). Multivariate logistic regression showed that elevated UHR levels were significantly associated with increased MASLD risk (adjusted OR = 1.057, 95% CI: 1.016-1.100, p = 0.006), after adjusting for age, diabetes duration, BMI, blood pressure, and biochemical confounders.Conclusion: Elevated UHR is independently associated with MASLD in T2DM patients, suggesting its clinical relevance in MASLD screening among this high-risk population.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1459-1466"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067459/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S520688","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Patients with type 2 diabetes mellitus (T2DM) exhibit an elevated risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). The uric acid to high-density lipoprotein cholesterol ratio (UHR) has emerged as a novel metabolic biomarker implicated in MASLD pathogenesis. This study aimed to evaluate the association between UHR and MASLD in a T2DM population.

Methods: In this cross-sectional study, we analyzed clinical data from 1081 T2DM patients (464 without MASLD, 617 with MASLD). Physiological and biochemical parameters were collected and analyzed. UHR was calculated as [uric acid (mg/dL)/HDL-C (mg/dL)] × 100%. Univariate and multivariate logistic regression analyses were performed to examine the association between UHR and MASLD.

Results: T2DM patients with MASLD had significantly higher UHR levels than those without MASLD (12.12[9.06-16.83] vs 10.36[7.65-14.08], p<0.001). UHR showed a strong positive correlation with TG/HDL (r =0.673, p < 0.001), moderate correlations with TG (r = 0.516, p < 0.001) and TC/HDL (r =0.548, p < 0.001), weak but significant associations with BMI (r = 0.330), WHR (r = 0.289), HOMA-IR (r = 0.121), ALT (r = 0.123), and GGT (r = 0.267) (all p < 0.05). Multivariate logistic regression showed that elevated UHR levels were significantly associated with increased MASLD risk (adjusted OR = 1.057, 95% CI: 1.016-1.100, p = 0.006), after adjusting for age, diabetes duration, BMI, blood pressure, and biochemical confounders.

Conclusion: Elevated UHR is independently associated with MASLD in T2DM patients, suggesting its clinical relevance in MASLD screening among this high-risk population.

查看原文本刊更多论文

2型糖尿病患者尿酸与HDL-C比值与代谢功能障碍相关脂肪变性肝病的相关性：一项横断面研究

背景：2型糖尿病（T2DM）患者发生代谢功能障碍相关脂肪变性肝病（MASLD）的风险升高。尿酸与高密度脂蛋白胆固醇比率（UHR）已成为一种新的代谢生物标志物，与MASLD的发病机制有关。本研究旨在评估T2DM人群中UHR和MASLD之间的关系。方法：在这项横断面研究中，我们分析了1081例T2DM患者的临床资料（464例无MASLD， 617例有MASLD）。收集和分析生理生化参数。UHR计算为[尿酸(mg/dL)/HDL-C (mg/dL)] × 100%。采用单因素和多因素logistic回归分析来检验UHR和MASLD之间的关系。结果：T2DM合并MASLD患者UHR水平显著高于未合并MASLD患者（12.12[9.06-16.83]vs 10.36[7.65-14.08], pr =0.673, p < 0.001），与TG （r = 0.516, p < 0.001）、TC/HDL （r =0.548, p < 0.001）呈正相关，与BMI （r = 0.330）、WHR （r = 0.289）、HOMA-IR （r = 0.121）、ALT （r = 0.123）、GGT （r = 0.267）呈弱相关性（均p < 0.05）。多因素logistic回归显示，在调整了年龄、糖尿病病程、BMI、血压和生化混杂因素后，UHR水平升高与MASLD风险增加显著相关（校正OR = 1.057, 95% CI: 1.016-1.100, p = 0.006）。结论：UHR升高与T2DM患者MASLD独立相关，提示其在这一高危人群中筛查MASLD的临床相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.